HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $6

Benzinga Newsdesk www.benzinga.com Positive 77.7%

Neg 0% Neu 0% Pos 77.7%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spero Therapeutics (NASDAQ:SPRO) with a Buy and raises the price target from $5 to $6.